MOD-GRF 1-29

1. What is it?

GRF and GHRH are names for the hormone that signals the pituitary gland to release GH. The notation 1-29 means a fragment containing the first 29 amino acids, while MOD indicates modification. In the form discussed, four positions in the chain have been changed. This helps explain the difference from sermorelin, which corresponds to the unmodified active GHRH fragment. However, the word modified alone does not justify a conclusion that a medicine is more effective or safer. [86] [66]

2. Why do people turn to it?

MOD-GRF 1-29 has a separate catalogue entry because readers may encounter the name independently of CJC-1295 No DAC. The evidence generally concerns the same chemical variant, not a second independent treatment. Advertised goals include GH stimulation and better body composition. Available documentation lacks suitable clinical studies confirming these benefits for a clearly defined MOD-GRF form. A different label does not increase the number or strength of studies. [86]

3. How does it work?

Chain modifications affect receptor interactions and susceptibility to breakdown. Studies of GRF analogues began in the 1980s, testing individual changes in rats and pigs. This is the family's development history, not proof of present human uses. MOD-GRF without DAC lacks the extra component for persistent albumin binding and should not inherit descriptions of original CJC-1295's multi-day effects. [89] [85] [86]

4. What do studies actually show?

A 2010 product analysis found a 29-amino-acid peptide matching the structure marketed as CJC-1295 without DAC. Methods established composition and amino-acid sequence. This is useful chemical evidence, but involved no patients and did not measure fat loss, wound healing, sleep or functioning. Identifying a substance and demonstrating a therapeutic effect are different questions requiring different methods. [87] [86]

5. What do we still not know?

Sermorelin data cannot substitute for MOD-GRF data simply because both molecules relate to the 1-29 fragment. Results for CJC with DAC also cannot establish how long MOD-GRF acts. Mixtures with ipamorelin are another separate issue: their effects and risks may differ. Without a sound study of the combination, it is unknown whether the added ingredient improves the effect, leaves it unchanged or increases unwanted reactions. [86] [81]

6. What are the risks?

There is no reliable account of adverse-effect frequency during long-term use of this exact form. The FDA highlights this gap and peptide-material quality. Testing must distinguish the intended molecule from similar impurities and larger peptide clusters; a stated name is insufficient. Uncertainty must also be distinguished from proven danger. A firm safety assessment is impossible without appropriate human follow-up. [86]

In sport governed by WADA rules, this form belongs to the prohibited group of GHRH-mimicking substances. Although No DAC and MOD-GRF are not listed separately in the 2026 list, the ban covers the entire group. It also applies outside competition. [108] [86]

7. Is it an approved medicine?

MOD-GRF 1-29 is a chemical and commercial name, not an approved therapeutic indication. FDA documentation on the CJC family describes inconsistent naming and the absence of an approved product containing the forms assessed. Discussion of substances for pharmacy compounding in the USA does not create a medicine authorisation in Poland. The historical approval of Geref containing sermorelin does not automatically cover modified analogues either. Each specific product and use requires its own regulatory basis. [86] [65]

8. What is new in research?

A search completed on 3 November 2026 found no new direct clinical studies confirming the advertised benefits of MOD-GRF 1-29. The current position should therefore be described as insufficient evidence, rather than the discovery of a new way to aid recovery. The most valuable future update would be a study with a clearly defined molecular structure, product composition, participant group and assessment of noticeable effects. A publication about another GRF analogue or doping detection does not fill this gap. [86] [87] [88]

Where does this information come from?

References link to the publications and documents used. Each source includes its material type and what was reviewed; findings concern the substance, form and study population described.